



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : [concorddrugsLtd@gmail.com](mailto:concorddrugsLtd@gmail.com) Website : [www.concorddrugs.in](http://www.concorddrugs.in)

---

To,

Date: 13.02.2020

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 13.02.2020

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Thursday, 13.02.2020 at 05.00 p.m. at the registered office of the company, the Board considered and approved Un-Audited financial results along with Limited Review report for the quarter ended 31.12.2019. (enclosed).


The meeting concluded at 5:30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For Concord Drugs Limited

  
S. Nagi Reddy  
Chairman  
DIN: 01764665



Encl: as above



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st December 2019						
[Rs. in Lakhs]						
Particulars	Quarterly ended			Nine months Ended		Year ended
	31-Dec-19	30-Sep-19	31-Dec-18	April'19 to December'1	April'18 to December'18	31-Mar-19
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I Revenue from Operations</b>						
a. Net sales from Operations	1,090.56	1,409.43	921.00	3,831.06	3,373.27	4,807.72
b. Other Operating Income						
<b>II Other Income</b>	2.15	2.15	1.90	7.46	6.43	8.59
<b>III Total Revenue (I+II)</b>	<b>1,092.71</b>	<b>1,411.58</b>	<b>922.90</b>	<b>3,838.52</b>	<b>3,379.70</b>	<b>4,816.31</b>
<b>IV Expenses</b>						
a. Cost of Material Consumed	876.25	1,118.05	625.37	3,089.20	2,570.92	3,913.85
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-1.29	52.36	22.85	72.37	96.32	45.59
c. Employees Benefit Expenses	89.59	94.99	81.59	265.93	218.77	252.92
d. Finance Costs	40.10	44.62	39.90	127.41	120.32	159.30
e. Depreciation and Amortisation expense	36.89	36.84	54.86	110.11	163.83	171.18
f. Other expenses	44.82	56.33	92.78	140.45	191.95	229.50
<b>Total Expenses</b>	<b>1,086.35</b>	<b>1,403.19</b>	<b>917.35</b>	<b>3,805.47</b>	<b>3,362.11</b>	<b>4,772.33</b>
<b>V Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>6.36</b>	<b>8.39</b>	<b>5.55</b>	<b>33.05</b>	<b>17.59</b>	<b>43.98</b>
<b>VI Exceptional Items</b>						
<b>VII Profit/ (Loss) before tax (V-VI)</b>	<b>6.36</b>	<b>8.39</b>	<b>5.55</b>	<b>33.05</b>	<b>17.59</b>	<b>43.98</b>
<b>VIII Tax Expense:</b>	<b>1.93</b>	<b>2.75</b>	<b>1.87</b>	<b>9.54</b>	<b>-2.58</b>	<b>3.27</b>
a. Current tax	1.65	2.55	4.84	8.88	15.22	11.72
b. Deferred tax charge/credit	0.28	0.20	-2.97	0.66	-17.80	-8.44
c. MAT Credit						
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>4.43</b>	<b>5.64</b>	<b>3.68</b>	<b>23.51</b>	<b>20.17</b>	<b>40.70</b>
<b>X Other Comprehensive Income</b>						
Items that will not be reclassified to profit or loss						
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>4.43</b>	<b>5.64</b>	<b>3.68</b>	<b>23.51</b>	<b>20.17</b>	<b>40.70</b>
<b>XI Paid-up equity share capital</b> (Face value of the share- Rs. 10 each)	874.38	874.38	786.18	874.38	786.18	786.18
<b>Other Equity</b>	1,464.77	1,460.34	114.29	1,464.77	-	1,529.46
<b>XII Earnings per share (of Rs. 10 each)</b>						
<b>XIII a. Basic (in Rs)</b>	0.05	0.06	0.05	0.27	0.26	0.52
<b>b. Diluted (in Rs)</b>	0.05	0.06	0.05	0.27	0.26	0.52

**Notes:**

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) Prescribed under section 133 of the companies Act, 2013; read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th February, 2020
- The company operates in only one Segment viz., "Pharmaceutical Products"
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

Place: Hyderabad  
Date: 13-02-2020







**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Concord Drugs Limited,**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Concord Drugs Limited ('the company') for the quarter ended December 31, 2019 and the year to date from April 01, 2019 to December 31, 2019 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N.G Rao and Associates**  
**Chartered Accountants**  
**FRN: 009399S**



**G Nageswara Rao**  
**(Partner)**  
**MNo: 207300**  
**UDINNo:20207300AAAADG6522**

**Place: Hyderabad**  
**Date: 13-02-2020.**